Crystagen
SHORT PEPTIDE · KHAVINSON IMMUNE BIOREGULATOR · SEQUENCE UNCONFIRMED
also: immune peptide bioregulator · Crystagen Cytogen · EDP (unverified designation)
Crystagen is a short peptide from Khavinson's St Petersburg group marketed as an immune 'bioregulator'. The retrievable evidence is a handful of cell-culture immunology reports — B-lymphocyte activation in aged spleen preparations, effects on thymocyte blast transformation and signalling — all from the originating group. Its sequence could not be verified against PubChem or the primary literature, and secondary sources disagree about it.
// our evidence grade — unedited
Crystagen has the thinnest record of the five: a small number of in vitro immunology papers from the originating group, no animal outcome study, no human data, no registered trial — and its amino-acid sequence could not be confirmed from any authoritative source, with retail listings giving conflicting designations.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | Crystagen (short peptide immune bioregulator; sequence unconfirmed) |
| purity | ≥ 98% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Lyophilised powder is stored desiccated at -20 °C and protected from light. Once reconstituted, laboratory practice is refrigeration at 2-8 °C for short-term use, or aliquoting and freezing to avoid repeated freeze-thaw cycles. Handling information only; this compound has no approved human use. |
| solubility | Short hydrophilic peptide, readily soluble in sterile or bacteriostatic water and in dilute aqueous buffer. Lot-specific solubility is stated on the certificate of analysis. |
// select size
crypto payment · research use only · not for human consumption
// others in Other